Mounjaro®
Starting from £179.99/mo
Start journey Learn moreNausea is the most commonly reported side effect of Mounjaro (tirzepatide), affecting a significant proportion of people in the early weeks of treatment. It usually starts within a day or two of an injection and tends to settle as your body adjusts — most people find it most noticeable after the first pen or after a dose increase. The broader picture of Mounjaro side effects covers the full range, but if sickness is what brought you here right now, this page works through why it happens, how long to expect it, and what helps. These are prescription-only medicines; a prescriber assesses whether they are suitable for you before any treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Mounjaro activates two gut-hormone receptors: GIP and GLP-1. One of the downstream effects of that activation is slowed gastric emptying, food stays in your stomach longer than it normally would. That slowing is part of how the medicine reduces appetite, but it also means your stomach can feel uncomfortably full, especially if you eat a large meal or eat too quickly. That sensation reads as nausea.
The effect tends to be strongest in the first week or two after starting treatment or stepping up to a higher dose. Your digestive system is encountering a new signal, and the adjustment period is genuinely uncomfortable for some people. Tirzepatide-related nausea follows this same pattern regardless of what the medicine is called, because the mechanism is the same.
It helps to know this is not a sign that something is going wrong. The NHS tirzepatide patient page lists nausea, vomiting, diarrhoea and indigestion as the most common side effects, and notes that they are usually mild to moderate and tend to improve with time. Knowing why it is happening does not make it comfortable, but it does make it easier to ride out.
For most people, nausea is at its worst in the first week after a new dose and then gradually fades over the following one to two weeks. By the time the next injection comes around, many people feel largely back to normal. That is the pattern clinical trial participants reported, and it is consistent with what prescribers hear day to day.
A smaller group continues to feel nausea throughout treatment, particularly after injections. This does not automatically mean the medicine needs to stop, it can mean the dose is moving up faster than your body is ready for, or that some straightforward adjustments to eating habits would help. Practical strategies for managing Mounjaro nausea goes into this in more detail.
If sickness is severe, persistent beyond two to three weeks at a stable dose, or accompanied by the inability to keep any fluids down, that is a conversation to have with your prescribing team promptly. Dehydration from repeated vomiting is a genuine risk worth taking seriously.
Certain habits reliably make GI symptoms worse on tirzepatide. Large meals are the main one: a stomach that is already emptying slowly does not respond well to volume. Fatty or heavily processed foods, alcohol and eating quickly all add to the load. Some people also find that lying down shortly after eating amplifies the discomfort.
What tends to help: smaller, more frequent meals; prioritising protein and bland foods in the early weeks; staying well hydrated with sips rather than large quantities at once; and giving yourself a few minutes sitting upright after eating before moving around vigorously. None of this is a medical protocol, it is the practical experience that patients and prescribers report. Your prescriber and the Patient Information Leaflet that comes with your pen are the right sources for advice tailored to you.
If you are wondering about cost alongside managing side effects, our Mounjaro cost page covers what private treatment involves financially, including what is included in the consultation and aftercare you receive. Support with side effects is part of the service, not an add-on.
Most nausea from Mounjaro is uncomfortable but not dangerous. There are exceptions. In January 2026, the MHRA issued a Drug Safety Update on GLP-1 medicines specifically highlighting acute pancreatitis: a serious but infrequent side effect. The key symptom is severe stomach pain that does not ease and may spread through to the back, sometimes with vomiting. This is different from the ordinary nausea of starting treatment. If you experience it, seek urgent medical attention rather than waiting to see if it settles.
Other signals that need prompt attention: signs of significant dehydration (dizziness, very little urine, rapid heartbeat) from persistent vomiting, or a serious allergic reaction (swelling of the face or throat, difficulty breathing). The MHRA's Yellow Card scheme lets patients report suspected side effects directly, which contributes to the ongoing safety monitoring of newer medicines like Mounjaro.
If you have been managing ongoing sickness and want a clinical perspective on whether your current dose or injection timing could be adjusted, our Mounjaro sickness guidance and the wider resources around GI symptoms on tirzepatide are worth reading. And if you have not yet started treatment but are weighing everything up, you can start a free consultation with our prescribers, who review every application personally the same day it is submitted.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.